e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
argenx SE - American Depositary Shares
(NQ:
ARGX
)
822.13
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
822
Open
822.13
Bid (Size)
813.01 (40)
Ask (Size)
814.00 (40)
Prev. Close
822.13
Today's Range
822.13 - 822.13
52wk Range
510.06 - 934.62
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
2 Ways to Play the Big Pharma Patent Cliff
↗
Today 7:05 EDT
With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.
Via
MarketBeat
Topics
ETFs
Intellectual Property
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
May 08, 2026
From
argenx SE
Via
GlobeNewswire
Performance
YTD
-2.1%
-2.1%
1 Month
-0.8%
-0.8%
3 Month
-1.4%
-1.4%
6 Month
-7.8%
-7.8%
1 Year
+54.5%
+54.5%
More News
Read More
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
May 07, 2026
From
argenx SE
Via
GlobeNewswire
argenx to Present at BofA Securities 2026 Health Care Conference
May 06, 2026
From
argenx SE
Via
GlobeNewswire
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
May 06, 2026
From
argenx SE
Via
GlobeNewswire
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
April 30, 2026
From
argenx SE
Via
GlobeNewswire
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
April 18, 2026
From
argenx SE
Via
GlobeNewswire
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story
↗
March 21, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
↗
March 21, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
argenx announces Annual General Meeting of Shareholders on May 6, 2026
March 20, 2026
From
argenx SE
Via
GlobeNewswire
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund
↗
March 20, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
March 12, 2026
Via
Finterra
Topics
Economy
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch
↗
March 09, 2026
Via
Stocktwits
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
March 06, 2026
From
argenx SE
Via
GlobeNewswire
Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability
February 26, 2026
Via
Finterra
Topics
Earnings
Economy
Intellectual Property
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
February 26, 2026
From
argenx SE
Via
GlobeNewswire
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
February 26, 2026
From
argenx SE
Via
GlobeNewswire
argenx to Present at TD Cowen 46th Annual Healthcare Conference
February 23, 2026
From
argenx SE
Via
GlobeNewswire
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
February 19, 2026
From
argenx SE
Via
GlobeNewswire
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash
↗
February 17, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million
↗
February 17, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake
↗
February 17, 2026
Via
The Motley Fool
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More
↗
February 17, 2026
Via
The Motley Fool
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
February 06, 2026
Via
Finterra
Topics
ETFs
Economy
Initial Public Offering
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
January 13, 2026
From
argenx SE
Via
GlobeNewswire
Frequently Asked Questions
Is argenx SE - American Depositary Shares publicly traded?
Yes, argenx SE - American Depositary Shares is publicly traded.
What exchange does argenx SE - American Depositary Shares trade on?
argenx SE - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for argenx SE - American Depositary Shares?
The ticker symbol for argenx SE - American Depositary Shares is ARGX on the Nasdaq Stock Market
What is the current price of argenx SE - American Depositary Shares?
The current price of argenx SE - American Depositary Shares is 822.13
When was argenx SE - American Depositary Shares last traded?
The last trade of argenx SE - American Depositary Shares was at 05/14/26 04:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.